247 related articles for article (PubMed ID: 36726355)
1. Targeted thorium-227 conjugates as treatment options in oncology.
Karlsson J; Schatz CA; Wengner AM; Hammer S; Scholz A; Cuthbertson A; Wagner V; Hennekes H; Jardine V; Hagemann UB
Front Med (Lausanne); 2022; 9():1071086. PubMed ID: 36726355
[TBL] [Abstract][Full Text] [Related]
2. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effect of a Mesothelin-Targeted
Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Dizdarevic S; McCready R; Vinjamuri S
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):192-217. PubMed ID: 31471713
[TBL] [Abstract][Full Text] [Related]
5. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
6. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Wickstroem K; Karlsson J; Ellingsen C; Cruciani V; Kristian A; Hagemann UB; Bjerke RM; Ryan OB; Linden L; Mumberg D; Brands M; Cuthbertson A
Pharmaceuticals (Basel); 2019 Oct; 12(4):. PubMed ID: 31618864
[TBL] [Abstract][Full Text] [Related]
8. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.
Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
Drug Dev Ind Pharm; 2017 Sep; 43(9):1440-1449. PubMed ID: 28402142
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
10. Radium and other alpha emitters in prostate cancer.
Sartor O; Sharma D
Transl Androl Urol; 2018 Jun; 7(3):436-444. PubMed ID: 30050802
[No Abstract] [Full Text] [Related]
11. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.
Makvandi M; Dupis E; Engle JW; Nortier FM; Fassbender ME; Simon S; Birnbaum ER; Atcher RW; John KD; Rixe O; Norenberg JP
Target Oncol; 2018 Apr; 13(2):189-203. PubMed ID: 29423595
[TBL] [Abstract][Full Text] [Related]
12. Construction of a thorium/actinium generator at the Canadian Nuclear Laboratories.
Perron R; Gendron D; Causey PW
Appl Radiat Isot; 2020 Oct; 164():109262. PubMed ID: 32819503
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
15. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
16. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
[TBL] [Abstract][Full Text] [Related]
17. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
[TBL] [Abstract][Full Text] [Related]
18. An alternative radiochemical separation strategy for isolation of Ac and Ra isotopes from high energy proton irradiated thorium targets for further application in Targeted Alpha Therapy (TAT).
Baimukhanova A; Engudar G; Marinov G; Kurakina E; Dadakhanov J; Karaivanov D; Yang H; Ramogida CF; Schaffer P; Magomedbekov EP; Filosofov D; Radchenko V
Nucl Med Biol; 2022; 112-113():35-43. PubMed ID: 35797877
[TBL] [Abstract][Full Text] [Related]
19. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
20. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.
Takalkar A; Adams S; Subbiah V
Exp Hematol Oncol; 2014; 3():23. PubMed ID: 25243101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
